143 related articles for article (PubMed ID: 1206483)
1. Inhibition of drug metabolism by hydroxylated metabolites: cross-inhibition and specificity.
Soda DM; Levy G
J Pharm Sci; 1975 Dec; 64(12):1928-31. PubMed ID: 1206483
[TBL] [Abstract][Full Text] [Related]
2. Interindividual differences in rates of drug oxidation in man.
Davies DS; Thorgeirsson SS; Breckenridge A; Orme M
Drug Metab Dispos; 1973; 1(1):411-7. PubMed ID: 4149412
[No Abstract] [Full Text] [Related]
3. Interaction between metronidazole and drugs eliminated by oxidative metabolism.
Jensen JC; Gugler R
Clin Pharmacol Ther; 1985 Apr; 37(4):407-10. PubMed ID: 3979002
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P-450 and drug oxidation.
Davies DS
Biochem J; 1969 Dec; 115(5):23P-24P. PubMed ID: 4391248
[No Abstract] [Full Text] [Related]
5. Effects of nifedipine on hepatic drug oxidation.
Dickinson TH; Egan JM; Abernethy DR
Pharmacology; 1988; 36(6):405-10. PubMed ID: 3420161
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of enzyme induction on antipyrine metabolite formation.
Danhof M; Verbeek RM; van Boxtel CJ; Boeijinga JK; Breimer DD
Br J Clin Pharmacol; 1982 Mar; 13(3):379-86. PubMed ID: 7059438
[TBL] [Abstract][Full Text] [Related]
7. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
[TBL] [Abstract][Full Text] [Related]
8. Interindividual differences in drug oxidation: clinical importance.
Sjöqvist F; von Bahr C
Drug Metab Dispos; 1973; 1(1):469-82. PubMed ID: 4149420
[No Abstract] [Full Text] [Related]
9. Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.
Anadón A; Martinez-Larrañaga MR; Fernandez MC; Diaz MJ; Bringas P
Antimicrob Agents Chemother; 1990 Nov; 34(11):2148-51. PubMed ID: 2073104
[TBL] [Abstract][Full Text] [Related]
10. [Studies on the combination of drugs. IV. Effect of 4-hydroxyantipyrine and N-acetyl-p-aminophenol on the metabolism of phenylbutazone, oxyphenbutazone and ketophenylbutazone].
Niwa H; Nakayama T
Yakugaku Zasshi; 1968 Jul; 88(7):838-42. PubMed ID: 5750523
[No Abstract] [Full Text] [Related]
11. Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats.
Teunissen MW; Van Graft M; Vermeulen NP; Breimer DD
Xenobiotica; 1983 Aug; 13(8):497-502. PubMed ID: 6649682
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
Adedoyin A; Aarons L; Houston JB
Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749
[TBL] [Abstract][Full Text] [Related]
13. Antipyrine half-life and drug elimination.
Breckenridge A
Clin Pharmacokinet; 1980; 5(3):201-3. PubMed ID: 7389234
[No Abstract] [Full Text] [Related]
14. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.
Pond SM; Birkett DJ; Wade DN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):573-9. PubMed ID: 913025
[TBL] [Abstract][Full Text] [Related]
15. Specifity and sensitivity of the inhibition of drug metabolism following inhalation of carbon disulphide-air mixtures.
Freundt KJ; Kuttner P; Dreher W
Arzneimittelforschung; 1976; 26(5):793-9. PubMed ID: 989352
[TBL] [Abstract][Full Text] [Related]
16. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
[TBL] [Abstract][Full Text] [Related]
17. Drug displacement from protein-binding and redistributional interactions.
McQueen EG
Prog Biochem Pharmacol; 1974; 9():122-8. PubMed ID: 4140531
[No Abstract] [Full Text] [Related]
18. In vitro hepatic oxidative metabolism of antipyrine, phenytoin and phenylbutazone in rabbits with experimental renal failure.
van Peer AP; Belpaire FM; Bogaert MG
Arch Int Pharmacodyn Ther; 1978 Aug; 234(2):346-7. PubMed ID: 708161
[No Abstract] [Full Text] [Related]
19. In vitro hepatic oxidative metabolism of antipyrine, phenytoin and phenylbutazone in uraemic rabbits.
Van Peer AP; Belpaire FM; Bogaert MG
J Pharm Pharmacol; 1980 Feb; 32(2):135-6. PubMed ID: 6103036
[No Abstract] [Full Text] [Related]
20. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
